Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis

NCT01813812 is registered in ClinicalTrials.gov with Dong-A Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01813812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01813812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis
Lead sponsor
Dong-A Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2010
Completion date
Not reported
Enrollment
492 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute gastritis, chronic gastritis